重组组织型纤溶酶原激活剂治疗心源性脑栓塞的疗效与安全性分析

摘要/Abstract

摘要：

目的探讨重组组织型纤溶酶原激活剂（recombinant tissue plasminogen activator，rt-PA）治疗心源性脑栓塞的有效性与安全性。方法采用回顾性分析方法，非连续性选取北京积水潭医院2007年1月～2011年12月间发病4.5～12 h内的（前循环梗死发病4.5 h内，后循环12 h内）心源性脑栓塞患者45例，其中接受rt-PA溶栓治疗的22例患者为溶栓组，接受常规二级预防的23例作为对照组。收集患者牛津郡社区卒中项目（Oxfordshire Community Stroke Project，OCSP）分型、危险因素、既往史、用药史和神经功能缺损情况。比较两组患者基线（治疗前）、24 h、90 d神经系统功能缺损情况、预后良好的比例及两组间梗死后出血转化（hemorrhagic transformation，HT）的发生率以及90 d患者死亡率。结果两组患者基线美国国立卫生研究院卒中量表（National Institutes of Health Stroke Scale，NIHSS）评分及OCSP分型差异均无显著性。发病24 h后，溶栓组NIHSS改善分值［4.5（－1.5，8）］较对照组［0（0，3）］差异具有显著性（P=0.04）。溶栓组早期改善百分比（54.55%）高于对照组（34.78%），但差异无显著性。发病90 d，溶栓组NIHSS改善分值［9（7，11）］较对照组［3.5（2，4.75）］差异具有显著性（P＜0.01）。溶栓组预后良好百分比（22.7%～36.4%）较对照组（17.4%～26.1%）升高，但差异无显著性。溶栓组和对照组HT患者均为4例，其中症状性出血转化（symptomatic intracranial hemorrhage，sICH）每组各3例，溶栓组4例HT患者均无糖尿病病史，对照组4例患者均有糖尿病病史，6例sICH患者收缩压均大于140 mmHg。发病90 d，两组患者死亡例数均为3例，6例死亡患者入院时NIHSS分值普遍偏高，且梗死类型以完全前循环梗死（total anterior circulation infarct，TACI）为主。结论 rt-PA用于治疗心源性脑栓塞能够改善发病24 h、90 d的神经功能缺损程度，使用rt-PA相对安全。

文章导读： 本研究为rt-PA静脉溶栓治疗心源性脑栓塞患者的有效性、安全性提供了依据。

关键词: 重组组织型纤溶酶原激活剂; 脑梗死; 心源性脑栓塞; 静脉溶栓

Abstract:

Objective To investigate the effectiveness and safety of thrombolytic therapy for cardiogenic cerebral embolism by intravenous recombinant tissue plasminogen activator(rt-PA). Methods Retrospective analysis was used in this study. Forty five patients who was hospitalized between January 2007 and December 2011 in Beijing Jishuitan Hospital and suffered from cardiogenic cerebral embolism were selected. Twenty two patients were treated with rt-PA within 4.5~12 hours from the onset(4.5 hours for anterior circulation infarct and 12 hours for posterior circulation infarct) as thrombolytic group and 23 patients who accepted regular secondary prevention of acute ischemic stroke were selected as controls. The Oxfordshire Community Stroke Project(OCSP) classification, risk factors, past history and drug history and neurological deficits were collected. The neurological deficits, and the incidence of favorable outcome on the base line, 24th hour and 90th day were compared. The incidence of hemorrhagic transformation(HT) and mortality within 90 days were analyzed. Results There was no significant difference in the National Institutes of Health Stroke Scale(NIHSS) score and OCSP classification in the onset between both groups. On the time of 24 hours after the onset, the NIHSS score improved significantly in the thrombolytic group(4.5[-1.5, 8]) compared with the control group(0[0, 3])(P=0.04). The incidence of early improvement in the thrombolytic group(54.55%) increased compared with the control group(34.78%). But there was no significant difference in it between both groups. On the 90 days after onset, the NIHSS score improved significantly in the thrombolytic group(9[7,11]) compared with the control group(3.5[2, 4.75])(P<0.01). The incidence of favorable outcome in the thrombolytic group(22.7%~36.4%) increased compared with the control group(17.4%~26.1%). But there was no significant difference in it between both groups. There were 4 HT cases and 3 symptomatic intracranial hemorrhage(sICH) cases in each group. In the control group, all the 4 HT cases had diabetes history and the 4 cases in the thrombolytic group did not. The systolic blood pressure in the 6 sICH cases were over 140 mmHg. There were 3 death cases in each group within 90 days from the onset. All of the 6 cases had high score of NIHSS. The OCSP classification of most of the deaths was total anterior circulation infarct(TACI). Conclusion Giving rt-PA to the patients who suffered from cardiogenic cerebral embolism could improve the neurological deficits on the time of 24 hours and 90 days after the onset. Intravenous thrombolysis with rt-PA is relatively safe.

Key words: Recombinant tissue plasminogen activator; Acute cerebral infarction; Cardiogenic cerebral embolism; Intravenous thrombolysis

唐澍，闫立荣，孙玉衡，陈捷，胡洪涛. 重组组织型纤溶酶原激活剂治疗心源性脑栓塞的疗效与安全性分析[J]. 中国卒中杂志, 2013, 8(05): 360-367.

TANG Shu, YAN Li-Rong, SUN Yu-Heng, CHEN Jie, HU Hong-Tao.. Effectiveness and Safety of Thrombolytic Therapy for Cardiogenic Cerebral Embolism by Intravenous Recombinant Tissue Plasminogen Activator[J]. Chinese Journal of Stroke, 2013, 8(05): 360-367.

参考文献

马中华, 孙林, 田国红, 等. 170例急性脑梗死CISS分型及相关危险因素分析[J]. 中国卒中杂志, 2011, 10:772-777.

Bernhardt P, Schmidt H, Sommer T, et al. Atrial fibrillation-patients at high risk for cerebral embolism[J]. Clin Res Cardiol, 2006, 3:148-153.

闫立荣, 孙玉衡. 不同剂量重组组织型纤溶酶原激活剂静脉溶栓治疗对超早期急性脑梗死预后的影响[J]. 中国卒中杂志, 2008, 11:808-813.

王伊龙, 吴敌, 周永, 等. 中国七城市卒中患者急诊溶栓情况分析[J]. 中国卒中杂志, 2009, 4:23-28.

Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA stroke study group[J]. N Engl J Med, 1995, 24:1581-1587.

Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke[J]. N Engl J Med, 2008, 13:1317-1329.

Zhang B, Sun XJ, Ju CH. Thrombolysis with alteplase 4.5-6 hours after acute ischemic stroke[J]. Eur Neurol, 2011, 3:170-174.

Derex L, Nighoghossian N, Perinetti M, et al. Thrombolytic therapy in acute ischemic stroke patients with cardiac thrombus[J]. Neurology, 2001, 11:2122-2125.

李小刚. 卒中溶栓规范化管理:特殊临床状态的rt-PA溶栓治疗[J]. 中国卒中杂志, 2008, 8:612-617.

Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment[J]. Stroke, 1993, 1:35-41.

Bamford J, Dennis M, Sandercock P, et al. The frequency, causes and timing of death within 30 days of a first stroke:The Oxfordshire Community Stroke Project[J]. J Neurol Neurosurg Psychiatry, 1990, 10:824-829.

中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组. 中国急性缺血性脑卒中诊治指南2010[J]. 中华神经科杂志, 2010, 2:146-153.

饶明俐. 《中国脑血管病防治指南》摘要(三)[J]. 中风与神经疾病杂志, 2006, 1:4-8.

Yamaguchi T, Mori E, Minematsu K, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset:Japan alteplase clinical trial(J-ACT)[J]. Stroke, 2006, 7:1810-1815.

Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic transformation of ischemic brain tissue:Asymptomatic or symptomatic?[J]. Stroke, 2001, 6:1330-1335.

Fiorelli M, Bastianello S, von Kummer R, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct:Relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I(ECASS I) cohort[J]. Stroke, 1999, 11:2280-2284.

Yamaji K, Fujimoto S, Yutani C, et al. Is the site of thrombus formation in the left atrial appendage associated with the risk of cerebral embolism?[J]. Cardiology, 2002, 2:104-110.

吕鹤, 张巍, 袁云, 等. 颈内动脉粥样硬化易损斑块的炎细胞、平滑肌细胞和新生血管改变[J]. 中华神经科杂志, 2006, 9:583-586.

Molina CA, Montaner J, Arenillas JF, et al. Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes[J]. Stroke, 2004, 2:486-490.

Bluhmki E, Chamorro A, Davalos A, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke(ECASS III):Additional outcomes and subgroup analysis of a randomised controlled trial[J]. Lancet Neurol, 2009, 12:1095-1102.

Paciaroni M, Agnelli G, Corea F, et al. Early hemorrhagic transformation of brain infarction:Rate, predictive factors, and influence on clinical outcome:Results of a prospective multicenter study[J]. Stroke, 2008, 8:2249-2256.

苏敏, 杨卫新, 王万华, 等. 急性缺血性卒中重组组织型纤溶酶原激活剂静脉溶栓致出血性转化及其预后的危险因素分析[J]. 中华神经科杂志, 2011, 11:754-758.

Cronin CA, Shah N, Morovati T, et al. No increased risk of symptomatic intracerebral hemorrhage after thrombolysis in patients with European Cooperative Acute Stroke Study(ECASS) exclusion criteria[J]. Stroke, 2012, 6:1684-1686.

Al-Khaled M.Predictors of In-Hospital Mortality and the Risk of Symptomatic Intracerebral Hemorrhage after Thrombolytic Therapy with Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke[EB/OL]. (2012-05-10)[2013-04-23]. http://www.strokejournal.org/article/S1052-3057(12)00101-2/abstract.

Yong M, Kaste M. Association of characteristics of blood pressure profiles and stroke outcomes in the ECASS-II trial[J]. Stroke, 2008, 2:366-372.

Larrue V, von Kummer RR, Muller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator:A secondary analysis of the European-Australasian Acute Stroke Study(ECASS II)[J]. Stroke, 2001, 2:438-441.

陈小华, 苏镇培, 曾进胜, 等. 心源性脑栓塞的生存及预后影响因素研究[J]. 中国神经精神疾病杂志, 2003, 5:345-348.

[1]	鲁燕, 杨保荣, 黄向萍, 杨冠桂, 陈圣文, 李建荣, 曾小明. 县级医院急性缺血性卒中超时间窗经MRI筛选溶栓的病例对照研究 [J]. 中国卒中杂志, 2022, 17(12): 1321-1326.
[2]	李如娟, 杨川, 马晓辉, 侯焕峰, 付会杰, 马晓丹, 方军涛, 靳金灵, 杨金波. DSA评估无症状大脑中动脉闭塞患者侧支循环状态研究 [J]. 中国卒中杂志, 2022, 17(12): 1355-1359.
[3]	胡红梅, 杨磊, 于玲, 秦伟, 白明悦, 胡文立. 急性单发小脑小梗死的临床特征 [J]. 中国卒中杂志, 2022, 17(11): 1221-1226.
[4]	刘亚杰, 李玉娣, 黎凯锋, 陈哲锋, 凌莉. 基于高通量RNA-Seq技术探讨补阳还五汤治疗小鼠脑梗死的作用机制 [J]. 中国卒中杂志, 2022, 17(11): 1238-1246.
[5]	王磊, 周春亭, 方洋, 王朝晖. 2例椎动脉漂浮血栓的治疗体会[J]. 中国卒中杂志, 2022, 17(11): 1247-1251.
[6]	林庆金, 杨雅玲, 卢武生. 寰椎变异致反复脑梗死1例报道[J]. 中国卒中杂志, 2022, 17(11): 1252-1256.
[7]	罗秋雁, 黄文利, 冯慧宇, 陈玲, 周鸿雁. 脑室出血合并大面积脑梗死1例报道并文献复习[J]. 中国卒中杂志, 2022, 17(10): 1103-1107.
[8]	杨金波, 张英魁. 到底应该用面积还是用体积描述梗死病灶？[J]. 中国卒中杂志, 2022, 17(10): 1112-1113.
[9]	何俊芳, 刘新平, 吕学海, 王斌. PI3K/AKT信号通路介导脂联素对脑缺血再灌注大鼠的保护作用 [J]. 中国卒中杂志, 2022, 17(08): 857-862.
[10]	闫志杰, 曲庆明, 张淇, 张永丽, 樊启为, 吕海东, 贾杰. 缺血性卒中患者基于心肺适能个体化训练1例报告[J]. 中国卒中杂志, 2022, 17(06): 585-588.
[11]	徐冉, 李悦悦, 冯凡凡, 阚伟豪, 董瑞国. 肺癌相关脑梗死的危险因素分析[J]. 中国卒中杂志, 2022, 17(06): 628-633.
[12]	仲伟斌, 王鹏飞, 于进超, 张金彪, 李振光. 支架治疗颈动脉夹层导致急性脑梗死2例报告及文献复习[J]. 中国卒中杂志, 2022, 17(06): 653-657.
[13]	李婛, 黄燕兰, 钟一飞, 郭晓云. 以偏侧肢体舞蹈样动作为脑梗死首发症状的Trousseau综合征1例并文献分析[J]. 中国卒中杂志, 2022, 17(05): 535-538.
[14]	李言洵, 刘芳, 王丽, 汪慧, 何雯. 多发性脑梗死起病的噬血细胞综合征1例报道[J]. 中国卒中杂志, 2022, 17(05): 539-543.
[15]	杨卜凡, 邹新宇, 龚小沉, 都泓材, 陈忠伦, 唐宇凤, 李肇坤. 反应性红细胞增多症伴大脑前动脉夹层动脉瘤致脑梗死1例[J]. 中国卒中杂志, 2022, 17(03): 310-313.